Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,498 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Terminated Phase 2 Interventional

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

NCT00388609
View directory record Official record
Conditions
Obesity
Interventions
BMS-646256, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 18, 2026, 8:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 18, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

AGN-242428 in the Treatment of Plaque Psoriasis

NCT03339999
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
AGN-242428, Placebo
Drug
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

NCT05587998
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine, AZD4041, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 18, 2026, 8:43 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

NCT02596893
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
150
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Atenolol, Nebivolol, Propranolol, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips

NCT05574049
View directory record Official record
Conditions
Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia, Hyperglycemia
Interventions
Tetrahydrocannabivarin, Placebo
Drug · Other
Lead sponsor
Medical Life Care Planners, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 4 Interventional

Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes

NCT00433641
View directory record Official record
Conditions
Obesity
Interventions
sibutramine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)

NCT01421056
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

NCT04221945
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Pembrolizumab, Placebo for pembrolizumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

NCT03717272
View directory record Official record
Conditions
Marijuana Abuse
Interventions
AEF0117, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
21 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 18, 2026, 8:43 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 18, 2026, 8:43 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

NCT07218575
View directory record Official record
Conditions
Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
Interventions
Everolimus blinded oral capsules, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

NCT04196101
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Pelham, Alabama • Anaheim, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00847626
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Chlorthalidone, Azilsartan medoxomil
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
84
States / cities
Birmingham, Alabama • Columbiana, Alabama • Tuscaloosa, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

NCT03198078
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole (OPC-34712), Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03653026
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
114
States / cities
Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT04162769
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
35
States / cities
Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 18, 2026, 8:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07029945
View directory record Official record
Conditions
Geographic Atrophy
Interventions
BRX011, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
55 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Gilbert, Arizona • Phoenix, Arizona • Hattiesburg, Mississippi + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 18, 2026, 8:43 AM EDT
Completed Not applicable Interventional Results available

Cardiovascular Prevention for Persons With HIV

NCT00982189
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease Risk
Interventions
Pravastatin, Lisinopril
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
40 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 18, 2026, 8:43 AM EDT